For many people, they gradually improve as the body adjusts
BMC Complement Altern Med (2015) 15:410
For instance, liraglutide (Victoza), dulaglutide (Trulicity), and subcutaneous semaglutide (Ozempic) have data supporting risk reduction of major adverse cardiovascular events as well as preserving kidney function in patients with T2DM.(2)(3)(4) Another benefit of GLP-1 and GIP/GLP-1 receptor agonists is significant weight loss, specifically seen with liraglutide, semaglutide, and tirzepatide, which are now available as FDA approved products for weight management with the brand names Saxenda, Wegovy, and Zepbond respectively.(5)(6)(7) While these products have great glycemic, weight, and cardiovascular outcomes, the benefits have resulted in some detrimental repercussions
Mechanisms of the development of pulmonary hypertension in chronic hypoxia
Pancreatitis and gallbladder issues are rare but possible with all GLP-1 agonists